Pfizer denies Ranbaxy buyout talk

Pfizer said it isn't buying a majority stake in Ranbaxy Laboratories, quashing rumors that it might counter Daiichi Sankyo's bid for the Indian drugmaker. "I can tell you that we have no intention of buying the company," a spokesman told Dow Jones. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.